# CTLA4 (CD152): CD80/CD86 Competitive Binding, Regulatory T-Cell Function, and Cancer Immunotherapy


## Key Takeaways

- CTLA4 (CD152) is a critical immune checkpoint receptor that attenuates T-cell activation by competitively binding CD80 and CD86 ligands on antigen-presenting cells, thereby inhibiting the costimulatory CD28 pathway.
- Its constitutive expression on regulatory T cells (Tregs) and induction on conventional T cells are central to peripheral immune tolerance; genetic ablation leads to fatal lymphoproliferative disease.
- CTLA4 blockade with monoclonal antibodies like ipilimumab represents a paradigm shift in cancer therapy, enhancing anti-tumor immunity by releasing T-cell inhibition.
- Pathogenic germline mutations in *CTLA4* cause a complex immune dysregulation syndrome characterized by autoimmunity and immunodeficiency, while common SNPs are associated with susceptibility to various autoimmune diseases.
- CTLA4's function is mediated by both cell-extrinsic mechanisms, such as trans-endocytosis of CD80/CD86 by Tregs, and cell-intrinsic mechanisms, including dampening TCR signaling via phosphatase recruitment.
- Viruses like HCMV, HBV, HCV, and HIV exploit CTLA4 upregulation for immune evasion, and its blockade is being investigated in combination with oncolytic virotherapy for cancer treatment.

---

## Executive Summary & Key Metadata

Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), also designated CD152, is a critical immune checkpoint receptor that attenuates T-cell activation. It functions primarily by outcompeting the costimulatory receptor CD28 for binding to the B7 family ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APCs). CTLA4 is constitutively expressed on regulatory T cells (Tregs) and is induced on conventional T cells following activation. Its inhibitory signaling is central to peripheral immune tolerance, and its genetic ablation in mice results in fatal lymphoproliferative disease. In clinical oncology, CTLA4 blockade with the monoclonal antibody ipilimumab was the first immune checkpoint inhibitor approved for cancer therapy, marking a paradigm shift in oncology. This manual provides a comprehensive technical reference covering the genomic architecture, structural biology, signaling pathways, pathogenic mutations, and therapeutic targeting of CTLA4.

| **Attribute** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | CTLA4 |
| **UniProt Accession** | P16410 |
| **Representative PDB ID** | 1I8L |
| **Chromosomal Locus** | 2q33.2 (GRCh38: chr2:203,867,715-203,873,960) |
| **Primary Molecular Function** | Immune checkpoint receptor; competitive antagonist of CD28 for CD80/CD86; negative regulator of T-cell activation |
| **Disease & Pathology Associations** | Autoimmune susceptibility (type 1 diabetes, Graves' disease, celiac disease); CTLA4 haploinsufficiency (immune dysregulation); cancer immunotherapy target |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The human *CTLA4* gene is located on the long arm of chromosome 2 at cytogenetic band 2q33.2. The gene spans approximately 6.2 kilobases (kb) of genomic DNA on the plus strand. The locus is part of a conserved immune gene cluster that includes *CD28* and *ICOS* (Inducible T-cell COStimulator), which are arranged in tandem. The order on chromosome 2 is: centromere – *CD28* – *CTLA4* – *ICOS* – telomere. This syntenic arrangement is conserved across mammals, suggesting shared regulatory elements and evolutionary co-regulation.

The *CTLA4* gene comprises four exons and three introns. The canonical transcript (NM_005214.5) is 1,536 nucleotides in length, encoding a 223-amino-acid precursor protein. The exon-intron architecture is as follows:

- **Exon 1**: Encodes the 5' untranslated region (UTR) and the N-terminal signal peptide (amino acids 1–35).
- **Exon 2**: Encodes the immunoglobulin-like V-type extracellular domain (amino acids 36–161), which contains the CD80/CD86 ligand-binding site.
- **Exon 3**: Encodes the transmembrane domain (amino acids 162–187) and the beginning of the cytoplasmic tail.
- **Exon 4**: Encodes the remainder of the cytoplasmic domain (amino acids 188–223) and the 3' UTR.

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter of *CTLA4* lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for several transcription factors critical for T-cell biology. Key regulatory elements include:

- **NFAT (Nuclear Factor of Activated T-cells)**: Binding sites for NFAT are located within the proximal promoter region. NFAT is a master regulator of T-cell activation and directly induces *CTLA4* transcription following T-cell receptor (TCR) engagement.
- **[FOXP3](/knowledge/bioinformatics/genes/immunology-checkpoints/foxp3-gene-structure-function-pathway) (Forkhead Box P3)**: In regulatory T cells, FOXP3 binds directly to the *CTLA4* promoter and intronic enhancer regions, driving high-level constitutive expression. This is a defining feature of Tregs.
- **AP-1 (Activator Protein-1)**: Composite NFAT:AP-1 binding sites are present, integrating TCR and costimulatory signals.
- **STAT (Signal Transducer and Activator of Transcription)**: Cytokine signaling, particularly through IL-2 and common gamma-chain cytokines, activates STAT5, which binds to the *CTLA4* locus to promote expression.

### 1.3 Enhancer Elements and 3D Chromatin Architecture

Beyond the proximal promoter, several cis-regulatory elements (CREs) have been identified. A highly conserved intronic enhancer within intron 1 is critical for FOXP3-mediated expression in Tregs. Chromatin conformation capture studies (Hi-C) have demonstrated that the *CTLA4* promoter physically interacts with this intronic enhancer in Tregs, forming a chromatin loop that is permissive for transcription. Additionally, a distal enhancer located downstream of the *ICOS* gene has been shown to regulate *CTLA4* expression in a lineage-specific manner.

DNA methylation at the *CTLA4* locus is dynamically regulated. In naive T cells, the promoter is partially methylated, correlating with low expression. Upon T-cell activation, demethylation occurs at specific CpG dinucleotides, facilitating transcription. In Tregs, the *CTLA4* locus is constitutively demethylated, a feature used as a marker for stable Treg identity.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *CTLA4* generates multiple isoforms with distinct functions:

- **Full-length CTLA4 (flCTLA4)**: The canonical membrane-bound receptor encoded by all four exons. This is the primary functional isoform on the cell surface.
- **Soluble CTLA4 (sCTLA4)**: Generated by the use of an alternative splice site that skips exon 3 (the transmembrane domain). This results in a frameshift and a premature stop codon, producing a secreted protein that retains the ligand-binding domain. sCTLA4 can bind CD80/CD86 and act as a decoy, further inhibiting costimulation. Elevated sCTLA4 levels are observed in several autoimmune diseases.
- **Ligand-independent CTLA4 (liCTLA4)**: A rare isoform that lacks exon 2 (the ligand-binding domain). This isoform is retained intracellularly and may play a role in intracellular signaling, though its physiological significance is less well-defined.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The CTLA4 protein is a type I transmembrane glycoprotein. The mature protein, after cleavage of the 35-amino-acid signal peptide, consists of 188 amino acids. The domain architecture from the N-terminus to the C-terminus is:

1.  **Signal Peptide (aa 1–35)**: Directs the nascent polypeptide to the endoplasmic reticulum (ER) for co-translational translocation.
2.  **Extracellular Immunoglobulin V-like Domain (aa 36–161)**: This is the ligand-binding domain. It adopts a classic immunoglobulin variable (IgV) fold, characterized by two beta-sheets held together by a conserved disulfide bond (Cys54–Cys110). This domain is responsible for high-affinity binding to CD80 and CD86.
3.  **Transmembrane Domain (aa 162–187)**: A hydrophobic alpha-helix that anchors the protein in the plasma membrane. This domain is critical for dimerization; a conserved cysteine residue (Cys180) within the transmembrane region forms an interchain disulfide bond, stabilizing the CTLA4 homodimer on the cell surface.
4.  **Cytoplasmic Tail (aa 188–223)**: A short intracellular domain of 36 amino acids that lacks intrinsic enzymatic activity. It contains two key signaling motifs: a YVKM motif (Tyr201-Val202-Lys203-Met204) and a proline-rich motif (PxxP). These motifs mediate interactions with downstream signaling proteins.

### 2.2 Quaternary Structure: The Homodimer

CTLA4 exists as a covalent homodimer on the cell surface. The dimerization is mediated by the disulfide bond at Cys180 in the transmembrane domain. The dimeric structure is functionally significant because it allows CTLA4 to bind bivalently to its ligands, CD80 and CD86, which themselves form homodimers. This bivalent interaction dramatically increases the avidity of CTLA4 for its ligands, allowing it to outcompete CD28, which binds monovalently.

### 2.3 Ligand Binding: The CD80/CD86 Interface

The crystal structure of the CTLA4 extracellular domain in complex with CD80 (PDB: 1I8L) and CD86 has been solved at high resolution. The binding interface is dominated by the complementarity-determining region-like loops (CDR1, CDR2, and CDR3) of the IgV domain. Key residues involved in ligand binding include:

- **The MYPPPY motif (Met99-Tyr100-Pro101-Pro102-Pro103-Tyr104)**: This highly conserved hexapeptide motif is located in the CDR3-like loop and is essential for binding to both CD80 and CD86. Mutations in this motif abolish ligand binding.
- **The CDR1-like loop**: Residues in this loop, including Lys36 and Glu42, contribute to the binding energy.
- **The CDR2-like loop**: This loop contains residues that interact with the GFCC' face of the ligand.

The binding affinity of CTLA4 for CD80 (Kd ≈ 0.2–0.4 µM) is approximately 10- to 20-fold higher than its affinity for CD86 (Kd ≈ 2–4 µM). This differential affinity is physiologically relevant, as CD80 is upregulated later in the immune response and provides a stronger inhibitory signal through CTLA4.

### 2.4 Post-Translational Modifications

- **N-linked Glycosylation**: CTLA4 has three potential N-linked glycosylation sites (Asn78, Asn111, and Asn116) in the extracellular domain. Glycosylation is critical for proper protein folding, stability, and cell-surface expression. The glycosylation state also influences the avidity of ligand binding.
- **Phosphorylation**: The cytoplasmic tail is subject to phosphorylation. Serine and threonine phosphorylation, particularly at Ser191 and Thr225, regulates the intracellular trafficking of CTLA4. Phosphorylation of Tyr201 within the YVKM motif creates a docking site for the SH2 domain of the phosphatidylinositol 3-kinase (PI3K) p85 subunit, although the functional significance of this interaction in CTLA4 signaling remains debated.

### 2.5 Interactive 3D Visualizer

For a hands-on exploration of the CTLA4 structure, including the ligand-binding interface and dimerization domain, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load CTLA4 (PDB: 1I8L)](/tools/protein-structure-viewer?source=direct&pdbId=1I8L)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The B7/CD28/CTLA4 Axis

The primary function of CTLA4 is to regulate the amplitude of T-cell activation by modulating the B7-CD28 costimulatory pathway. The activation of a naive T cell requires two signals:

1.  **Signal 1 (Antigen-specific)**: The TCR recognizes a peptide antigen presented on an MHC molecule on the APC.
2.  **Signal 2 (Costimulatory)**: CD28 on the T cell binds to CD80/CD86 on the APC, providing a potent costimulatory signal that promotes T-cell survival, proliferation, and cytokine production.

CTLA4 acts as a competitive antagonist of CD28. Because CTLA4 has a much higher affinity for CD80/CD86 than CD28, it can effectively outcompete CD28 for ligand binding, thereby depriving the T cell of costimulatory signals. This is the dominant mechanism of CTLA4 function.

### 3.2 Cell-Extrinsic vs. Cell-Intrinsic Mechanisms

CTLA4 employs both cell-extrinsic and cell-intrinsic mechanisms to suppress immune responses:

**Cell-Extrinsic Mechanisms (Treg-mediated):**

- **Competitive Ligand Sequestration**: Tregs constitutively express high levels of CTLA4. By binding to CD80/CD86 on APCs, Tregs can physically strip these ligands from the APC surface via a process called trans-endocytosis. This involves the Treg internalizing the CTLA4-ligand complex, thereby reducing the availability of costimulatory ligands for neighboring effector T cells.
- **Induction of Indoleamine 2,3-Dioxygenase (IDO)**: Engagement of CD80/CD86 on APCs by CTLA4 can trigger reverse signaling into the APC, leading to the upregulation of IDO. IDO catabolizes tryptophan into kynurenines, which are immunosuppressive metabolites that inhibit T-cell proliferation and promote Treg differentiation.

**Cell-Intrinsic Mechanisms (Signaling into the T cell):**

- **Competition for Ligand**: As described above, CTLA4 outcompetes CD28 for CD80/CD86 binding, reducing the positive signal.
- **Inhibition of TCR Signaling**: Upon ligand engagement, CTLA4 is recruited to the immunological synapse. The cytoplasmic tail of CTLA4 recruits protein phosphatase 2A (PP2A). PP2A dephosphorylates key signaling molecules in the TCR signaling cascade, including the CD3ζ chain and ZAP-70, thereby dampening TCR signal transduction.
- **Inhibition of Lipid Raft Recruitment**: CTLA4 engagement disrupts the organization of lipid rafts at the T-cell synapse, preventing the coalescence of signaling complexes.

### 3.3 Intracellular Trafficking and Regulation

The cell-surface expression of CTLA4 is tightly regulated by a process of continuous endocytosis and recycling. In resting T cells, CTLA4 is predominantly localized in intracellular vesicles. The YVKM motif in the cytoplasmic tail binds to the clathrin adaptor protein AP-2, which targets CTLA4 for clathrin-mediated endocytosis. Upon TCR stimulation, this interaction is disrupted (likely through phosphorylation of Tyr201), allowing CTLA4 to be released and trafficked to the cell surface. This dynamic regulation ensures that CTLA4 is rapidly mobilized to the synapse upon T-cell activation.

### 3.4 Protein-Protein Interaction Network

The CTLA4 signaling complex is relatively simple compared to other receptors. Key interacting proteins include:

- **CD80/CD86**: The primary ligands.
- **AP-2 (Adaptor Protein Complex 2)**: Mediates clathrin-dependent endocytosis.
- **PP2A (Protein Phosphatase 2A)**: Mediates dephosphorylation of TCR signaling components.
- **PI3K (Phosphatidylinositol 3-Kinase)**: Binds to the phosphorylated YVKM motif; its role is context-dependent.
- **FOXP3**: A transcription factor that directly regulates CTLA4 expression in Tregs.

### 3.5 Mermaid Diagram: CTLA4 Signaling Pathway

```mermaid
sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant Treg as "Regulatory T Cell"
    participant Teff as "Effector T Cell"
    Note over APC: Expresses CD80/CD86
    Note over Treg: Constitutively expresses CTLA4
    Note over Teff: Expresses CD28 and TCR

    APC->>Teff: MHC-peptide (Signal 1)
    APC->>Teff: CD80/CD86 binds CD28 (Signal 2)
    Teff-->>Teff: Full activation, proliferation, cytokine release

    Treg->>APC: CTLA4 binds CD80/CD86 (high affinity)
    APC--xTeff: CD80/CD86 sequestered, no Signal 2
    Treg->>Treg: Trans-endocytosis of CD80/CD86
    Treg->>APC: Reverse signaling -> IDO upregulation
    APC-->>Teff: Kynurenines (immunosuppressive)
    Teff-->>Teff: Anergy, apoptosis, or suppression
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 CTLA4 Haploinsufficiency and Immune Dysregulation

Germline mutations in *CTLA4* cause a complex immune dysregulation syndrome characterized by autoimmunity and immunodeficiency. This condition, often referred to as CTLA4 haploinsufficiency, is inherited in an autosomal dominant manner. Loss-of-function mutations in one allele result in reduced CTLA4 expression and function, leading to a failure of immune tolerance.

The clinical phenotype is highly variable but commonly includes:

- **Common Variable Immunodeficiency (CVID)-like features**: Hypogammaglobulinemia, recurrent infections.
- **Autoimmune Cytopenias**: Autoimmune hemolytic anemia, immune thrombocytopenia.
- **Enteropathy**: Severe inflammatory bowel disease.
- **Lymphocytic Organ Infiltration**: Enlargement of lymph nodes, spleen, liver, and lungs due to infiltration by lymphocytes.

### 4.2 Specific Pathogenic Variants

More than 100 pathogenic or likely pathogenic variants have been identified in *CTLA4*. These include missense, nonsense, frameshift, and splice-site mutations. The mutations are distributed throughout the gene, but certain regions are mutational hotspots.

| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **Domain Affected** | **Pathogenic Mechanism** | **Clinical Phenotype** |
| :--- | :--- | :--- | :--- | :--- | :--- |
| c.442C>T | p.Arg148* | Nonsense | Extracellular | Premature stop codon; likely nonsense-mediated decay | Severe immune dysregulation |
| c.436G>A | p.Gly146Arg | Missense | Extracellular | Disrupts IgV domain folding and ligand binding | CVID, autoimmune cytopenias |
| c.457A>G | p.Thr153Ala | Missense | Extracellular | Impairs cell-surface expression | Enteropathy, recurrent infections |
| c.458C>T | p.Thr153Ile | Missense | Extracellular | Impairs ligand binding | Autoimmune enteropathy |
| c.550C>T | p.Arg184Trp | Missense | Transmembrane | Disrupts dimerization | Immune dysregulation |
| c.589G>A | p.Gly197Arg | Missense | Cytoplasmic | Alters signaling motifs | Late-onset autoimmunity |
| c.627C>A | p.Tyr209* | Nonsense | Cytoplasmic | Truncates cytoplasmic tail | Severe lymphoproliferation |

### 4.3 Association with Common Autoimmune Diseases

In addition to monogenic disorders, common single-nucleotide polymorphisms (SNPs) in the *CTLA4* locus are associated with susceptibility to several autoimmune diseases. The most extensively studied is the +49A/G SNP (rs231775), which results in a Thr17Ala substitution in the signal peptide. The G allele (Ala17) is associated with reduced CTLA4 expression and function and is a risk factor for:

- **Type 1 Diabetes (T1D)**
- **Graves' Disease**
- **Hashimoto's Thyroiditis**
- **Celiac Disease**
- **Rheumatoid Arthritis**

The mechanism by which this SNP affects CTLA4 function is not fully understood but may involve altered signal peptide cleavage efficiency or protein trafficking.

### 4.4 Somatic Mutations in Cancer

Somatic mutations in *CTLA4* are relatively uncommon in tumors. However, truncating mutations and copy-number loss have been reported in a small fraction of cancers, potentially contributing to an enhanced anti-tumor immune response. Conversely, some tumors may upregulate CTLA4 expression on tumor-infiltrating lymphocytes as a mechanism of immune evasion.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Immune Evasion

Several viruses have evolved mechanisms to exploit the CTLA4 pathway to evade the host immune response.

- **Human Cytomegalovirus (HCMV)**: HCMV encodes a viral [IL-10](/knowledge/bioinformatics/genes/immunology-checkpoints/il10-gene-structure-function-pathway) homolog (cmvIL-10) that can upregulate CTLA4 expression on T cells and APCs, contributing to immune suppression during persistent infection.
- **Hepatitis B and C Viruses (HBV/HCV)**: Chronic HBV and HCV infections are associated with T-cell exhaustion, characterized by sustained high expression of inhibitory receptors, including CTLA4. This upregulation is driven by persistent antigen stimulation and contributes to the failure of the immune system to clear the virus.
- **Human Immunodeficiency Virus (HIV)**: HIV infection leads to chronic immune activation and T-cell exhaustion. CTLA4 is upregulated on HIV-specific CD4+ and CD8+ T cells, correlating with viral load and disease progression. CTLA4 blockade has been explored as a strategy to reverse exhaustion and enhance anti-HIV immunity.
- **Lymphocytic Choriomeningitis Virus (LCMV)**: In the mouse model of chronic LCMV infection, CTLA4 is co-expressed with PD-1 on exhausted T cells. Blockade of CTLA4, particularly in combination with PD-1 blockade, can partially reinvigorate exhausted T cells.

### 5.2 Bacterial and Parasitic Interactions

- **Mycobacterium tuberculosis**: The immune response to *M. tuberculosis* is tightly regulated. CTLA4 expression is increased on T cells during active tuberculosis, contributing to immune suppression and bacterial persistence.
- **Plasmodium spp. (Malaria)**: During malaria infection, CTLA4 is upregulated on Tregs, which may limit the development of effective anti-parasitic immunity. CTLA4 blockade has been shown to enhance protective immunity in mouse models of malaria.

### 5.3 Cancer Immunotherapy and Viral Oncolysis

The interaction between CTLA4 and viral infections has implications for cancer immunotherapy. Oncolytic viruses are being developed as cancer therapeutics. The anti-tumor immune response generated by oncolytic viruses can be enhanced by combining them with CTLA4 blockade, which removes inhibitory signals and allows for a more robust T-cell response.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Monoclonal Antibodies (Immune Checkpoint Inhibitors)

CTLA4 is a validated target for cancer immunotherapy. Monoclonal antibodies that block CTLA4 function have revolutionized the treatment of several cancers.

| **Drug Name** | **Type** | **Target** | **FDA-Approved Indications** | **Mechanism of Action** |
| :--- | :--- | :--- | :--- | :--- |
| **Ipilimumab (Yervoy)** | Fully human IgG1κ monoclonal antibody | CTLA4 | Unresectable or metastatic melanoma; adjuvant treatment of stage III melanoma; in combination with nivolumab for various cancers (e.g., renal cell carcinoma, colorectal cancer with MSI-H/dMMR, hepatocellular carcinoma, non-small cell lung cancer) | Binds to CTLA4 and blocks its interaction with CD80/CD86, thereby enhancing T-cell activation and anti-tumor immunity. The IgG1 isotype may also mediate antibody-dependent cell-mediated cytotoxicity (ADCC) against Tregs in the tumor microenvironment. |
| **Tremelimumab** | Fully human IgG2 monoclonal antibody | CTLA4 | Approved in combination with durvalumab (anti-PD-L1) for unresectable hepatocellular carcinoma | Blocks CTLA4 interaction with CD80/CD86. The IgG2 isotype has reduced ADCC activity compared to IgG1. |

### 6.2 [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles) and Biomarkers

The response to CTLA4 blockade is highly variable. Several potential biomarkers are being investigated:

- **[Tumor Mutational Burden](/knowledge/bioinformatics/tumor-mutational-burden-tmb-and-computational-scoring) (TMB)**: High TMB is associated with improved response to immune checkpoint inhibitors, including anti-CTLA4 therapy.
- **PD-L1 Expression**: While primarily used for PD-1/PD-L1 inhibitors, PD-L1 expression may also correlate with response to combination therapy.
- **Tumor-Infiltrating Lymphocytes (TILs)**: The density and composition of TILs, particularly the ratio of CD8+ effector T cells to Tregs, can predict response.
- **Genetic Polymorphisms**: SNPs in *CTLA4* (e.g., rs231775) have been investigated as potential predictors of response and immune-related adverse events (irAEs), but results are inconclusive.

### 6.3 Investigational Agents and Next-Generation Therapies

- **Bispecific Antibodies**: Bispecific antibodies targeting both CTLA4 and PD-1 or PD-L1 are in clinical development. These agents aim to co-block two checkpoints simultaneously, potentially improving efficacy.
- **Antibody-Drug Conjugates (ADCs)**: ADCs that deliver a cytotoxic payload to CTLA4-expressing Tregs are being explored to selectively deplete Tregs within the tumor microenvironment.
- **PROTACs (Proteolysis-Targeting Chimeras)**: Small molecules that induce the degradation of CTLA4 are in preclinical development. These agents could provide an alternative to antibodies, potentially with improved tissue penetration.
- **Small-Molecule Inhibitors**: The development of small-molecule inhibitors of CTLA4 has been challenging due to the protein-protein interaction nature of its ligand binding. However, peptide-based inhibitors and small molecules that disrupt the CTLA4-CD80/CD86 interaction are being explored.

### 6.4 Management of Immune-Related Adverse Events (irAEs)

The therapeutic benefit of CTLA4 blockade is often accompanied by immune-related adverse events (irAEs), which can affect any organ system. Common irAEs include colitis, dermatitis, hepatitis, and endocrinopathies. Management typically involves corticosteroids and, in severe cases, other immunosuppressants such as infliximab (anti-TNFα). The pharmacogenomics of irAE susceptibility is an active area of research.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 1493 | Gene-specific information, genomic context, and links to related records. |
| **Ensembl** | ENSG00000163599 | Genome assembly, transcripts, and variation data. |
| **UniProtKB** | P16410 | Protein sequence, function, post-translational modifications, and structure. |
| **RCSB PDB** | 1I8L | Experimentally determined 3D structure of the CTLA4-CD80 complex. |
| **HGNC** | 2505 | Official gene symbol and nomenclature. |
| **OMIM** | 123890 | Mendelian inheritance and disease associations. |
| **ClinVar** | 1493 | Human variations and their relationship to human health. |
| **STRING** | 9606.ENSP00000303978 | Protein-protein interaction networks. |
| **BioGRID** | 106670 | Physical and genetic interactions. |
| **Gene Ontology (GO)** | GO:0004888 (transmembrane signaling receptor activity); GO:0007165 (signal transduction); GO:0006955 (immune response) | Functional annotations. |
| **PharmGKB** | PA27032 | Pharmacogenomic information and drug-gene associations. |
| **The Cancer Genome Atlas (TCGA)** | CTLA4 | Expression and mutation data across cancer types. |

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1.  Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994). CTLA-4 can function as a negative regulator of T cell activation. *Immunity*, 1(5), 405–413. [https://doi.org/10.1016/1074-7613(94)90071-x](https://doi.org/10.1016/1074-7613(94)90071-x)
2.  Krummel, M. F., & Allison, J. P. (1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. *The Journal of Experimental Medicine*, 182(2), 459–465. [https://doi.org/10.1084/jem.182.2.459](https://doi.org/10.1084/jem.182.2.459)
3.  Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity*, 3(5), 541–547. [https://doi.org/10.1016/1074-7613(95)90125-6](https://doi.org/10.1016/1074-7613(95)90125-6)
4.  Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995). Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. *Science*, 270(5238), 985–988. [https://doi.org/10.1126/science.270.5238.985](https://doi.org/10.1126/science.270.5238.985)
5.  Leach, D. R., Krummel, M. F., & Allison, J. P. (1996). Enhancement of antitumor immunity by CTLA-4 blockade. *Science*, 271(5256), 1734–1736. [https://doi.org/10.1126/science.271.5256.1734](https://doi.org/10.1126/science.271.5256.1734)
6.  Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., Stahl, M. L., Seehra, J., Somers, W. S., & Mosyak, L. (2001). Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. *Nature*, 410(6828), 608–611. [https://doi.org/10.1038/35069118](https://doi.org/10.1038/35069118)
7.  Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., … Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. *The New England Journal of Medicine*, 363(8), 711–723. [https://doi.org/10.1056/NEJMoa1003466](https://doi.org/10.1056/NEJMoa1003466)
8.  Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., Hou, T. Z., Futter, C. E., Anderson, G., Walker, L. S., & Sansom, D. M. (2011). Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. *Science*, 332(6029), 600–603. [https://doi.org/10.1126/science.1202947](https://doi.org/10.1126/science.1202947)
9.  Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J. N., Tran, D. Q., Stoddard, J., Zhang, Y., Frucht, D. M., Dumitriu, B., Scheinberg, P., Folio, L. R., Frein, C. G., Price, S., Koh, C., Heller, T., Seroogy, C. M., … Uzel, G. (2014). Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. *Science*, 345(6204), 1623–1627. [https://doi.org/10.1126/science.1255904](https://doi.org/10.1126/science.1255904)
10. Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B. S., Schäffer, A. A., Grüning, B. A., Unger, S., Frede, N., Baumann, U., Witte, T., Schmidt, R. E., Dueckers, G., Niehues, T., Seneviratne, S., Kanariou, M., … Grimbacher, B. (2014). Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. *Nature Medicine*, 20(12), 1410–1416. [https://doi.org/10.1038/nm.3746](https://doi.org/10.1038/nm.3746)
11. Walker, L. S., & Sansom, D. M. (2015). Confusing signals: recent progress in CTLA-4 biology. *Trends in Immunology*, 36(2), 63–70. [https://doi.org/10.1016/j.it.2014.12.001](https://doi.org/10.1016/j.it.2014.12.001)
12. Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018). CTLA-4: a moving target in immunotherapy. *Blood*, 131(1), 58–67. [https://doi.org/10.1182/blood-2017-06-741033](https://doi.org/10.1182/blood-2017-06-741033)